Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: Long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist

European Cytokine Network

Volumn 20, Issue 4, 2009, Pages 225-234

  Alessi, Patrizia ^a   Leali, Daria ^a   Camozzi, Maura ^a   Cantelmo, AnnaRita ^b   Albini, Adriana ^b   Presta, Marco ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

Author keywords

Angiogenesis; Antiangiogenic therapy; Endothelium; FGF2; Pentraxins; Tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTOTOXIC AGENT; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 2 ANTAGONIST; FLUOROURACIL; PENTRAXIN 3; RECOMBINANT ALPHA INTERFERON; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

AMINO TERMINAL SEQUENCE; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; BREAST CANCER; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CHEMICAL ANALYSIS; CHEMICAL STRUCTURE; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT INDICATION; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; C-REACTIVE PROTEIN; DRUG RESISTANCE, NEOPLASM; FIBROBLAST GROWTH FACTOR 2; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; SERUM AMYLOID P-COMPONENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 72249111162     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2009.0175     Document Type: Review

References (112)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4.
2. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401.
3. Grandis JR, Argiris A. Targeting angiogenesis from pre-malignancy to metastases. Cancer Prev Res (Phila Pa) 2009; 2: 291.
4. Cao Y, Linden P, Farnebo J, et al. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc Natl Acad Sci U S A 1998; 95: 14389. (Pubitemid 28549377)
5. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273.
6. Dempke WC, Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer 2009; 45: 1117.
7. Zaidi SH, Huddart RA, Harrington KJ. Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol 2009; 6: 103.
8. Shannon AM, Williams KJ. Antiangiogenics and radiotherapy. J Pharm Pharmacol 2008; 60: 1029.
9. Nieder C, Wiedenmann N, Andratschke NH, et al. Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience. Rev Recent Clin Trials 2007; 2: 163. (Pubitemid 47554836)
10. Tortora G, Gelardi T, Ciardiello F, et al. The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. Int J Biol Markers 2007; 22: S47. (Pubitemid 46730022)
11. Cooney MM, van Heeckeren W, Bhakta S, et al. Drug insight: vascular disrupting agents and angiogenesis - novel approaches for drug delivery. Nat Clin Pract Oncol 2006; 3: 682. (Pubitemid 44843126)
12. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335. (Pubitemid 38702844)
13. Brower V. Antiangiogenesis research is booming, as questions and studies proliferate. J Natl Cancer Inst 2009; 101: 780.
14. Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963. (Pubitemid 27098025)
15. Folkman J. Looking for a good endothelial address. Cancer Cell 2002; 1: 113.
16. Dorrell MI, Aguilar E, Scheppke L, et al. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci U S A 2007; 104: 967. (Pubitemid 46154720)
17. Yu JL, Rak JW, Coomber BL, et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002; 295: 1526.
18. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299. (Pubitemid 41443415)
19. Brower V. How Well Do Angiogenesis Inhibitors Work? Biomarkers of Response Prove Elusive. J Natl Cancer Inst 2009; 101: 846.
20. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet 2004; 20: 563. (Pubitemid 39314564)
21. Fantl WJ, Escobedo JA, Martin GA, et al. Distinct phosphotyrosines on a growth factor receptor bind to specific molecules that mediate different signaling pathways. Cell 1992; 69: 413.
22. Javerzat S, Auguste P, Bikfalvi A. The role of fibroblast growth factors in vascular development. Trends Mol Med 2002; 8: 483.
23. Dell'Era P, Belleri M, Stabile H, et al. Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. Oncogene 2001; 20: 2655. (Pubitemid 32525296)
24. Redington AE, Roche WR, Madden J, et al. Basic fibroblast growth factor in asthma: measurement in bronchoalveolar lavage fluid basally and following allergen challenge. J Allergy Clin Immunol 2001; 107: 384. (Pubitemid 32173920)
25. Kanazawa S, Tsunoda T, Onuma E, et al. VEGF, basic-FGF, and TGF-beta in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation. Am J Gastroenterol 2001; 96: 822. (Pubitemid 32240738)
26. Yamashita A, Yonemitsu Y, Okano S, et al. Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats. J Immunol 2002; 168: 450. (Pubitemid 34014148)
27. Gibran NS, Isik FF, Heimbach DM, et al. Basic fibroblast growth factor in the early human burn wound. J Surg Res 1994; 56: 226.
28. Presta M, Dell'Era P, Mitola S, et al. Fibroblast growth factor/ fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159. (Pubitemid 40616114)
29. Ornitz DM, Xu J, Colvin JS, et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996; 271: 15292. (Pubitemid 26195013)
30. Nicoli S, De Sena G, Presta M. Fibroblast Growth Factor 2- induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. J Cell Mol Med 2008; in press.
31. Gualandris A, Rusnati M, Belleri M, et al. Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Differ 1996; 7: 147. (Pubitemid 26049823)
32. Jackson JR, Seed MP, Kircher CH, et al. The codependence of angiogenesis and chronic inflammation. Faseb J 1997; 11: 457.
33. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249.
34. Schmid MC, Varner JA. Myeloid cell trafficking and tumor angiogenesis. Cancer Lett 2007; 250: 1.
35. Aggarwal BB, Vijayalekshmi RV, Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 2009; 15: 425.
36. Presta M, Andres G, Leali D, et al. Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. Eur Cytokine Netw 2009; 20: 39.
37. Andres G, Leali D, Mitola S, et al. A Pro-inflammatory Signature Mediates FGF2-induced Angiogenesis. J Cell Mol Med 2008; in press.
38. Ribatti D, Vacca A, Rusnati M, et al. The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. Cytokine Growth Factor Rev 2007; 18: 327. (Pubitemid 46891290)
39. Stavri GT, Zachary IC, Baskerville PA, et al. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation 1995; 92: 11.
40. Seghezzi G, Patel S, Ren CJ, et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol 1998; 141: 1659. (Pubitemid 28309179)
41. Zubilewicz A, Hecquet C, Jeanny JC, et al. Two distinct signalling pathways are involved in FGF2-stimulated proliferation of choriocapillary endothelial cells: a comparative study with VEGF. Oncogene 2001; 20: 1403. (Pubitemid 32291191)
42. Im E, Kazlauskas A. Regulating angiogenesis at the level of PtdIns-4,5-P2. Embo J 2006; 25: 2075.
43. Stahl A, Paschek L, Martin G, et al. Combinatory inhibition of VEGF and FGF2 is superior to solitary VEGF inhibition in an in vitro model of RPE-induced angiogenesis. Graefes Arch Clin Exp Ophthalmol 2009; 247: 767.
44. Slaton JW, Perrotte P, Inoue K, et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 2726. (Pubitemid 29493945)
45. Kaban LB, Mulliken JB, Ezekowitz RA, et al. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a. Pediatrics 1999; 103: 1145.
46. Marler JJ, Rubin JB, Trede NS, et al. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics 2002; 109: E37.
47. Kaban LB, Troulis MJ, Ebb D, et al. Antiangiogenic therapy with interferon alpha for giant cell lesions of the jaws. J Oral Maxillofac Surg 2002; 60: 1103.
48. Yamayoshi T, Nagayasu T, Matsumoto K, et al. Expression of keratinocyte growth factor/fibroblast growth factor-7 and its receptor in human lung cancer: correlation with tumour proliferative activity and patient prognosis. J Pathol 2004; 204: 110. (Pubitemid 39214488)
49. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of antiangiogenesis strategies. Curr Pharm Des 2007; 13: 2025. (Pubitemid 47040487)
50. van Berkel V, Barrett J, Tiffany HL, et al. Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J Virol 2000; 74: 6741. (Pubitemid 30470656)
51. Parry CM, Simas JP, Smith VP, et al. A broad spectrum secreted chemokine binding protein encoded by a herpesvirus. J Exp Med 2000; 191: 573.
52. Fallon PG, Alcami A. Pathogen-derived immunomodulatory molecules: future immunotherapeutics? Trends Immunol 2006; 27: 470.
53. Rusnati M, Bugatti A, Mitola S, et al. Exploiting surface plasmon resonance (SPR) technology for the identification of fibroblast grwth factor-2 (FGF2) antagonist endowed with antiangiogenic activity. Sensors 2009; in press.
54. Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3, a nonredundant soluble pattern recognition receptor involved in innate immunity. Vaccine 2003; 21 (Suppl. 2): S43. (Pubitemid 36588649)
55. Leali D, Bianchi R, Bugatti A, et al. Fibroblast Growth Factor 2- antagonist Activity of a Long-Pentraxin 3-derived Antiangiogenic Pentapeptide. J Cell Mol Med 2009; in press.
56. Leali D, Alessi P, Coltrini D, et al. Antiangiogenic activity of the FGF2-antagonist long-pentraxin-3. Curr Pharm Des 2009 (in press).
57. Gewurz H, Zhang XH, Lint TF. Structure and function of the pentraxins. Curr Opin Immunol 1995; 7: 54.
58. Garlanda C, Bottazzi B, Bastone A, et al. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005; 23: 337. (Pubitemid 40563173)
59. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994; 15: 81.
60. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983; 34: 141.
61. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74.
62. Castell JV, Gomez-Lechon MJ, David M, et al. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 1990; 12: 1179.
63. Du Clos TW. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol Biol Rep 1996; 23: 253.
64. Nauta AJ, Daha MR, van Kooten C, et al. Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 2003; 24: 148.
65. Goodman AR, Cardozo T, Abagyan R, et al. Long pentraxins: an emerging group of proteins with diverse functions. Cytokine Growth Factor Rev 1996; 7: 191. (Pubitemid 27198077)
66. Breviario F, d'Aniello EM, Golay J, et al. Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992; 267: 22190.
67. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 1993; 150: 1804. (Pubitemid 23129656)
68. Bottazzi B, Garlanda C, Cotena A, et al. The long pentraxin PTX3 as a prototypic humoral pattern recognition receptor: interplay with cellular innate immunity. Immunol Rev 2009; 227: 9.
69. Introna M, Alles VV, Castellano M, et al. Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 1996; 87: 1862. (Pubitemid 26068902)
70. Alles VV, Bottazzi B, Peri G, et al. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 1994; 84: 3483. (Pubitemid 24352913)
71. Latini R, Maggioni AP, Peri G, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 2004; 110: 2349. (Pubitemid 39407338)
72. Nauta AJ, de Haij S, Bottazzi B, et al. Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int 2005; 67: 543. (Pubitemid 40139846)
73. Bussolati B, Peri G, Salvidio G, et al. The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol 2003; 170: 1466. (Pubitemid 36139516)
74. Presta M, Camozzi M, Salvatori G, et al. Role of the soluble pattern recognition receptor PTX3 in vascular biology. J Cell Mol Med 2007; 11: 723. (Pubitemid 47313297)
75. Camozzi M, Rusnati M, Bugatti A, et al. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem 2006; 281: 22605. (Pubitemid 44242289)
76. Inforzato A, Rivieccio V, Morreale AP, et al. Structural characterization of PTX3 disulfide bond network and its multimeric status in cumulus matrix organization. J Biol Chem 2008; 283: 10147.
77. Giusti B, Fibbi G, Margheri F, et al. A model of antiangiogenesis: differential transcriptosome profiling of microvascular endothelial cells from diffuse systemic sclerosis patients. Arthritis Res Ther 2006; 8: R115.
78. Rusnati M, Camozzi M, Moroni E, et al. Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. Blood 2004; 104: 92. (Pubitemid 38879843)
79. Richard C, Liuzzo JP, Moscatelli D. Fibroblast growth factor-2 can mediate cell attachment by linking receptors and heparan sulfate proteoglycans on neighboring cells. J Biol Chem 1995; 270: 24188.
80. Leali D, Belleri M, Urbinati C, et al. Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. J Biol Chem 2001; 276: 37900. (Pubitemid 37384037)
81. Ribatti D, Gualandris A, Bastaki M, et al. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res 1997; 34: 455. (Pubitemid 28008032)
82. Nicoli S, De Sena G, Presta M. Fibroblast Growth Factor 2- induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. J Cell Mol Med 2008; in press.
83. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61: 253.
84. Nicoli S, Presta M. The zebrafish/tumor xenograft angiogenesis assay. Nat Protoc 2007; 2: 2918.
85. Giavazzi R, Giuliani R, Coltrini D, et al. Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. Cancer Res 2001; 61: 309. (Pubitemid 32095732)
86. Margheri F, Serrati S, Lapucci A, et al. Systemic sclerosis-endothelial cell anti-angiogenic PTX3 and MMP12 control human breast cancer tumor vascularization and development in mice. Neoplasia 2009; in press.
87. Willeke F, Assad A, Findeisen P, et al. Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur J Cancer 2006; 42: 2639. (Pubitemid 44442954)
88. Fazzini F, Peri G, Doni A, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 2001; 44: 2841. (Pubitemid 34016204)
89. Peri G, Introna M, Corradi D, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000; 102: 636. (Pubitemid 30640663)
90. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666.
91. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329.
92. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16.
93. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293. (Pubitemid 46630787)
94. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125. (Pubitemid 46089673)
95. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358: 2039.
96. Loges S, Mazzone M, Hohensinner P, et al. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15: 167.
97. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232.
98. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220.
99. Baruah P, Dumitriu IE, Peri G, et al. The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol 2006; 80: 87. (Pubitemid 44835529)
100. Bottazzi B, Vouret-Craviari V, Bastone A, et al. Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 1997; 272: 32817. (Pubitemid 28023616)
101. Inforzato A, Peri G, Doni A, et al. Structure and function of the long pentraxin PTX3 glycosidic moiety: fine-tuning of the interaction with C1q and complement activation. Biochemistry 2006; 45: 11540. (Pubitemid 44454002)
102. Nauta AJ, Bottazzi B, Mantovani A, et al. Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 2003; 33: 465. (Pubitemid 36267612)
103. Roumenina LT, Ruseva MM, Zlatarova A, et al. Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry 2006; 45: 4093.
104. Deban L, Jarva H, Lehtinen MJ, et al. Binding of the long pentraxin PTX3 to factor H: interacting domains and function in the regulation of complement activation. J Immunol 2008; 181: 8433.
105. Mantovani A, Garlanda C, Doni A, et al. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol 2008; 28: 1.
106. Diniz SN, Nomizo R, Cisalpino PS, et al. PTX3 function as an opsonin for the dectin-1-dependent internalization of zymosan by macrophages. J Leukoc Biol 2004; 75: 649. (Pubitemid 38405656)
107. Jeannin P, Bottazzi B, Sironi M, et al. Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. Immunity 2005; 22: 551. (Pubitemid 40719191)
108. Reading PC, Bozza S, Gilbertson B, et al. Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J Immunol 2008; 180: 3391.
109. Scarchilli L, Camaioni A, Bottazzi B, et al. PTX3 interacts with inter-alpha-trypsin inhibitor: implications for hyaluronan organization and cumulus oophorus expansion. J Biol Chem 2007; 282: 30161. (Pubitemid 350035268)
110. Salustri A, Garlanda C, Hirsch E, et al. PTX3 plays a key role in the organization of the cumulus oophorus extracellular matrix and in in vivo fertilization. Development 2004; 131: 1577. (Pubitemid 38559284)
111. Rovere P, Peri G, Fazzini F, et al. The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 2000; 96: 4300.
112. Duzhyy D, Harvey M, Sokolowski B. A secretory-type protein, containing a pentraxin domain, interacts with an A-type K+ channel. J Biol Chem 2005; 280: 15165. (Pubitemid 40562871)